Ausgabe 2/2020
Inhalt (16 Artikel)
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Andrej Janež, Cristian Guja, Asimina Mitrakou, Nebojsa Lalic, Tsvetalina Tankova, Leszek Czupryniak, Adam G. Tabák, Martin Prazny, Emil Martinka, Lea Smircic-Duvnjak
Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel
Sanjay Kalra, A. K. Das, Sarita Bajaj, Gagan Priya, Sujoy Ghosh, R. N. Mehrotra, Sambit Das, Parag Shah, Vaishali Deshmukh, Debmalya Sanyal, Sruti Chandrasekaran, Deepak Khandelwal, Amaya Joshi, Tiny Nair, Fatimah Eliana, Hikmat Permana, M. D. Fariduddin, Pradeep Krishna Shrestha, Dina Shrestha, Shayaminda Kahandawa, Manilka Sumanathilaka, Ahamed Shaheed, Aly Ahmed Abdel Rahim, Abbas Orabi, Ahmed Al-ani, Wiam Hussein, Dinesh Kumar, Khalid Shaikh
A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
Gian Paolo Fadini, Nikolaos Tentolouris, Irene Caballero Mateos, Virginia Bellido Castañeda, Cristóbal Morales Portillo
Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective Study
Irene Romera, Silvia Díaz, Antoni Sicras-Mainar, Flora López-Simarro, Tatiana Dilla, Esther Artime, Jesús Reviriego
Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study
Tsvetalina Tankova, Atanaska Elenkova, Ralitsa Robeva, Roumyana Dimova, Anna-Maria Borissova, Adrian Olszewski, Vasil Lachev, Reneta Petkova
Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
Tibor Hidvégi, Zoltán Balogh, Viktor Vass, Gábor Kovács, Péter Stella
Adherence to Medication, Diet and Physical Activity and the Associated Factors Amongst Patients with Type 2 Diabetes
Alireza Mirahmadizadeh, Haniyeh Khorshidsavar, Mozhgan Seif, Mohammad Hossein Sharifi
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
Chantal Mathieu, S. John Weisnagel, Peter Stella, Jacques Bruhwyler, Kathy Alexandre
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Josep Vidal, Samuel J. P. Malkin, Barnaby Hunt, Virginia Martín, Nino Hallén, Francisco Javier Ortega
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
Fumiko Yamamoto, Rie Ikeda, Kaori Ochiai, Tetsuaki Hirase, Naoyuki Hayashi, Tomoo Okamura
Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database
Corinne Emery, Elodie Torreton, Sylvie Dejager, Laurie Levy-Bachelot, Sébastien Bineau, Bruno Detournay
Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Yumie Takeshita, Takehiro Kanamori, Takeo Tanaka, Yuka Kaikoi, Yuki Kita, Noboru Takata, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Kenichi Harada, Toshifumi Gabata, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
Thomas R. Pieber, Lars Bardtrum, Joakim Isendahl, Lily Wagner, Rimei Nishimura
Correction to: The Association Between Phosphorylated Neurofilament Heavy Chain (pNF-H) and Small Fiber Neuropathy (SFN) in Patients with Impaired Glucose Tolerance
Yu-peng Li, Zhong-qing Yan, Li-ping Han, Ai-li Yin, Jin-yong Xu, Ya-ran Zhai, Sai Hao, Lin Zhang, Yun Xie
Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora